24/7 Market News Snapshot 10 March, 2025 – Tenaya Therapeutics, Inc. Common Stock (NASDAQ:TNYA)

March 10, 2025

DENVER, Colo., 10 March, 2025 (247marketnews.com) – (NASDAQ:TNYA) are discussed in this article.
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is actively advancing its innovative gene therapy pipeline with significant milestones achieved in its clinical trials targeting heart disease. As of today, the stock opened at $0.532 but saw a decline to $0.502, reflecting a decrease of approximately 10.33% from a prior close of $0.455 amid increased trading volume of 17.04 million shares. This trend underscores investor volatility and potential profit-taking, highlighting the need for close monitoring of volume dynamics and support levels as TNYA navigates market fluctuations.

On the clinical front, Tenaya has commenced dosing in Cohort 2 of the MyPEAK™-1 Phase 1b/2 clinical trial evaluating TN-201 for patients with MYBPC3-associated hypertrophic cardiomyopathy (HCM). The promising early data from Cohort 1 has garnered recognition, with a late-breaker presentation slated at the American College of Cardiology Scientific Sessions in March 2025. The company’s CEO, Faraz Ali, emphasized the significance of the recent $48.9 million financing, which is expected to enhance efforts in progressing their gene therapy initiatives into late-stage development.

Further bolstering its pipeline, Tenaya is making progress with TN-401, targeting plakophilin-2 (PKP2)-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), with initial data from the RIDGE™-1 Phase 1b clinical trial anticipated in the latter half of 2025. In a commitment to expand understanding of the disease’s impact, Tenaya is also leading the MyClimb study, focusing on the health burden in over 200 pediatric patients diagnosed with MYBPC3 mutations.

With strategic hires such as the appointment of Hiro Higa as Senior Vice President of Finance and the recent granting of a pivotal patent for TN-301, which addresses heart failure with preserved ejection fraction, Tenaya is positioned for a transformative year that aims to redefine treatment paradigms in cardiovascular care and significantly improve patient outcomes.

Related news for (TNYA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.